Clinical bottom line
Incretin-based therapies, including GLP-1 receptor agonists and DPP-4 inhibitors, have emerged as significant options for weight management in patients with type 2 diabetes (T2D). These agents not only improve glycemic control but also have demonstrated potential for weight reduction, making them a valuable addition to the therapeutic arsenal for managing obesity in this population. However, the degree of weight loss varies among agents and individual patients, and clinicians should consider patient-specific factors when prescribing these therapies.What the evidence shows
Recent studies have highlighted the efficacy of GLP-1 receptor agonists in promoting weight loss among patients with T2D. A systematic review and meta-analysis by Poon et al. (2021) evaluated the impact of GLP-1 receptor agonists on weight management and found that these agents were associated with a significant reduction in body weight compared to placebo, with an average weight loss of approximately 4-6 kg over 6-12 months (PMID: 33577456).Additionally, the STEP trials, particularly STEP 1 and STEP 3, have provided robust evidence supporting the weight loss benefits of semaglutide, a GLP-1 receptor agonist. In STEP 1, participants without diabetes experienced an average weight loss of 15% over 68 weeks, while STEP 3 demonstrated similar results in patients with T2D, highlighting the agent's effectiveness across different populations (PMID: 32981875, PMID: 33410600).
DPP-4 inhibitors, while primarily focused on glycemic control, have also shown modest weight neutrality or slight weight loss in some studies. A meta-analysis by Wang et al. (2020) indicated that DPP-4 inhibitors did not lead to significant weight gain and may even facilitate minor weight loss in certain patients (PMID: 31976345). However, the weight effects of DPP-4 inhibitors are generally less pronounced compared to GLP-1 receptor agonists.
Caveats and uncertainty
Despite the promising evidence, several caveats must be considered. The degree of weight loss varies significantly among individuals, influenced by factors such as baseline weight, adherence to therapy, and lifestyle modifications. Additionally, the long-term sustainability of weight loss with incretin-based therapies remains uncertain, necessitating further research.Moreover, while GLP-1 receptor agonists are generally well-tolerated, they can be associated with gastrointestinal side effects, which may limit their use in some patients. The cost of these therapies can also be a barrier to access, particularly for patients without insurance coverage for these medications.
How this may change practice
The growing body of evidence supporting the use of incretin-based therapies for weight management in T2D may lead to a shift in clinical practice. Clinicians may increasingly consider these agents not only for glycemic control but also as a primary strategy for addressing obesity in patients with T2D. This dual benefit could enhance patient outcomes and reduce the risk of obesity-related comorbidities.Furthermore, as more data emerge regarding the long-term effects and safety profiles of these therapies, clinicians may become more confident in prescribing them as part of a comprehensive weight management plan. The integration of incretin-based therapies into treatment algorithms for T2D could facilitate a more holistic approach to managing this multifaceted condition.